Form 4: Warburg Pincus Sells 18M SHC Shares in Secondary Offering

Warburg Pincus entities, a 10% owner and director, sold 18 million shares of Sotera Health Co common stock for $15.651 per share in a pre-planned secondary offering.

Summary

• Warburg Pincus & Co. and associated entities, collectively referred to as the 'Warburg Pincus Entities', reported a sale of Sotera Health Co (SHC) common stock.
• On November 10, 2025, the Warburg Pincus Entities sold a total of 18,000,000 shares of Common Stock in an underwritten public secondary offering.
• The shares were sold at a price of $15.651 per share.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following the offering, the Warburg Pincus Entities beneficially own 43,822,952 shares of Common Stock.
• This remaining beneficial ownership includes 14,405,046 shares held by Bull Holdco L.P. and 3,594,954 shares held by Bull Co-Invest L.P.

Sentiment

Score: 5

Explanation: The sale of a significant block of shares by Warburg Pincus, a major institutional investor and director, was executed under a pre-arranged Rule 10b5-1 plan. While this is a common private equity exit strategy and indicates a planned action rather than an immediate reaction to company performance, the large volume of shares sold could still create market pressure.

Negatives

• The sale of 18,000,000 shares by a significant institutional investor and director could create downward pressure on Sotera Health Co's stock price due to the increased supply in the market.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Warburg Pincus entities, who are 10% owners and have director representation, sold 18,000,000 shares of Sotera Health Co common stock in a secondary offering.

Stakeholder Impact

• Shareholders may experience short-term downward pressure on the stock price due to the large volume of shares entering the market.
• Existing shareholders may perceive the sale by a major institutional investor as a signal of reduced confidence, although it is a pre-planned exit.

Key Dates

Recommendation

The sale of 18 million shares by Warburg Pincus was conducted under a pre-arranged Rule 10b5-1 plan, which suggests a systematic exit strategy rather than a reaction to recent company performance. While this is a significant reduction in their stake and could lead to short-term market pressure due to the volume, it is an expected action for a private equity firm. Investors should hold to monitor how the market absorbs this supply and to assess the company's ongoing fundamentals, as the sale itself does not necessarily reflect a change in the company's intrinsic value.

Keywords

Sotera Health, SHC, Warburg Pincus, secondary offering, insider sale, beneficial ownership, Rule 10b5-1, private equity exit